Generation and pathogenicity of anti-platelet factor 4 antibodies: Diagnostic implications

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue SUPPL. 1, 1999, Pages

  Amiral, Jean ^a   Vissac, Anne Marie ^a  

^a HYPHEN Research   (France)

Author keywords

Antibodies; Heparin; Mechanisms; Pathogenicity; Platelet factor 4; Thrombocytopenia

Indexed keywords

HEPARIN; IMMUNOGLOBULIN G ANTIBODY; THROMBOCYTE FACTOR 4;

ANTIBODY DETECTION; CELL INTERACTION; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 0032748454     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/10760296990050s106     Document Type: Conference Paper

References (28)

1. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:137.
2. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia. Thromb Haemost 1992;68:95.
3. Greinacher A, Pōtzch B, Amiral J, et al. Heparin associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247.
4. Kelton G, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232.
5. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil activating peptide-2 in patients with heparin-associated-thrombocytopenia. Blood 1996; 88:410.
6. Kelton J. Pathophysiology of heparin-induced thrombocytopenia. Br J Haematol 1992;82:778.
7. Warkentin TE, Kelton JG. A 14-Year Study of heparin-induced thrombocytopenia. Am J Med 1996;101:502.
8. Reininger CB, Greinacher A, Graf J, et al. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 1996;81:641.
9. Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein Ib/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997;88:271.
10. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4 heparin complexes in heparin induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21.
11. 14-C serotonin release assay and heparin-platelet factor 4 ELISA for the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700.
12. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381.
13. Amiral J, Peynaud-Debayle E, Wolf M, et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low molecular weight heparin. Am J Hematol 1996;52:90.
14. Visentin GP, Malik M, Cyganiak KA, et al. Patients with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 1996;128:376.
15. Dunlop MG, Prowse CV, Dawes J. Heparin-induced platelet factor 4 release in patients with atherosclerotic peripheral vascular disease. Thromb Res 1987;46:409.
16. Amiral J, Marfaing-Koka A, Poncz M, et al. The biological basis of immune heparin-induced thrombocytopenia. Platelets 1998;9: 77.
17. Shoenfeld Y. Heparin-induced thrombocytopenia as an autoimmune disease - idiotypic evidence for the role of anti-heparin/PF4 autoantibodies. Isr J Med Sci 1997;33:243.
18. Amiral J, Wolf M, Fischer AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92:954.
19. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low molecular weight heparin. Clinical implications for heparin-induced thrombocytopenia. Circulation 1999;18:2530.
20. Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood 1975;45:345.
21. Pouplard C, Amiral J, Borg JY, et al. Differences in specificity of heparin-depcndent antibodies developed under low-molecular-weight-heparin therapy and higher cross-reactivity with Orgaran. Br J Haematol 1997;99:273.
22. Brandt JT, Osborne JM, Chacko G, et al. The role of FcγRIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995;73:1064.
23. Herbert JC, Savi P, Jeske WP, et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998;80:326.
24. Horne III MDK, Hutchison J. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998;58:24.
25. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin induced-thrombocytopenia. Blood 1998;92:3250.
26. Gruel Y, Lang M, Darnige L, et al. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 1990;336:1077.
27. Polgar J, Eichler P, Greinacher A, et al. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/ aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 1998;91:549.
28. Hach-Wunderle V, Kainer K, Krug B, et al. Heparin-associated thrombosis despite normal platelet counts. Lancet 1994;344:469.